Market Overview

Citigroup Reiterates Buy Rating, $31 PT on Ariad Pharmaceuticals

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

In a report published Friday, Citigroup reiterated its Buy rating and $31.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA).

Citigroup noted, “Today's announcement of the over 3 month early decision for the approval of Iclusig (ponatinib) in CML is a positive surprise, but the inclusion of a black box warning on the label was not in consensus expectation, in our view. We note that Tasigna has a black box warning and Sprycel, while no black box warning, has many warnings including pleural infusions (accumulation of fluid around the lungs).”

Ariad Pharmaceuticals closed on Thursday at $23.88.

Posted-In: CitigroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters